Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Allena Pharmaceuticals, Inc. (ALNA) stock declined over -25.10% intraday to trade at $0.19 a share on NASDAQ. The stock opened with a loss of -26.64% at $0.209 and touched an intraday high of $0.22, falling -25.49% against the last close of $0.255. The stock went to a low of $0.151 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $0.209 | $0.22 | $0.151 | $0.191 | 68,513,764 |
2022-06-29 | $0.259 | $0.44 | $0.235 | $0.255 | 576,064,300 |
2022-06-28 | $0.13 | $0.13 | $0.116 | $0.119 | 22,947,300 |
2022-06-27 | $0.124 | $0.128 | $0.121 | $0.126 | 1,967,000 |
2022-06-24 | $0.14 | $0.14 | $0.122 | $0.124 | 5,615,800 |
2022-06-23 | $0.124 | $0.135 | $0.119 | $0.133 | 4,300,800 |
2022-06-22 | $0.124 | $0.125 | $0.116 | $0.12 | 2,808,500 |
2022-06-21 | $0.12 | $0.126 | $0.116 | $0.117 | 3,781,200 |
2022-06-17 | $0.117 | $0.13 | $0.117 | $0.12 | 3,317,900 |
2022-06-16 | $0.119 | $0.128 | $0.116 | $0.117 | 8,819,700 |
Employees-
Beta1.76
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) stock price is $0.19 as of the last check on Thursday, June 30. During the trading session, ALNA stock reached the peak price of $0.22 while $0.151 was the lowest point it dropped to.
The NASDAQ listed ALNA is part of Biotechnology industry that operates in the broader Health Care sector. Allena Pharmaceuticals, Inc. , a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States.
Dr. Alexey L. Margolin
Co-Founder & Chairman
Dr. Louis Brenner
Pres, CEO & Director
Mr. Robert Gallotto
Co-Founder & Strategic Adviser
Dr. Richard D. Katz
CFO, Principal Financial Officer & Principal Accounting Officer
ALNA stock traded closed the last session at $0.191, which is $-0.06 or -25.10% lower than its previous close of $0.255. ALNA's current trading price is 179.65% lower than its 52-week high of $1.45 where as its distance from 52-week low of 0.07% is -86.83%.
Number of ALNA employees currently stands at -. ALNA operates from One Newton Executive Park, Suite 202, Newton, MA 02462, United States.
Official Webiste of $ALNA is: https://www.allenapharma.com
ALNA could be contacted at ALNA operates from One Newton Executive Park, Suite 202, Newton, MA 02462, United States, or at phone #617 467 4577 and can also be accessed through its website.
ALNA stock volume for the day was 68,431,536 shares while in the previous session number of ALNA shares traded was 68,513,764 . The average number of ALNA shares traded daily for last 3 months was 20.07 Million.
The percentage change in ALNA stock occurred in the recent session was -25.10% while the dollar amount for the price change in ALNA stock was $-0.06.
In the recent session, the day high for ALNA stock was $0.22 while the low for ALNA stock touched on the day was $0.151.
The market value of ALNA currently stands at 22.03 Million with its latest stock price at $0.19 and 89.38 Million of its shares outstanding.